Effects of umbilical cord mesenchymal stem cell transplantation on immune regulation and tissue damage in patients with ankylosing spondylitis

doi:10.3969/j.issn.2095-4344.2016.01.011

Abstract

Abstract:

BACKGROUND: Because of unique immunomodulatory properties, mesenchymal stem cells have become a research hotspot in the field of transplantation and the treatment of immune disease.
OBJECTIVE: To investigate the effect of umbilical cord mesenchymal stem cells on immune level and tissue injury in patients with ankylosing spondylitis.
METHODS: The clinical data of 61 patients with ankylosing spondylitis were analyzed retrospectively, and these
patients were divided into control group (n=33) and observation group (n=28) according to the treatment method, who were given immune and biological agents or umbilical cord mesenchymal stem cell infusion, respectively. All the patients were followed up for 12 months and at 12 months after treatment, therapeutic effect, immune level, disease activity index and adverse reactions were observed and compared between the two groups.
RESULTS AND CONCLUSION: The total effective rate was 89% in the observation group and 76% in the control group, and there was a significant difference between groups. At 12 months after treatment, erythrocyte sedimentation rate and other indicators were improved in all the patients, especially in the observation group (P < 0.05); the disease activity index scores were reduced gradually in the two groups, which were significantly lower in the observation group than the control group beginning at 3 months after treatment (P < 0.05). In the observation group, one case presented with injection extravasation and then the injection was successfully completed after re-choice of the blood vessel; two cases had mild fever, and their temperature returned to normal after active physical cooling. These findings indicate that umbilical cord mesenchymal stem cells for ankylosing spondylitis can remarkably improve the immune level, reduce tissue damage and result in little adverse effects in patients.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R318

Wang Jun, Chen Lu . Effects of umbilical cord mesenchymal stem cell transplantation on immune regulation and tissue damage in patients with ankylosing spondylitis[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(1): 60-64.

Figures/Tables 4

References

[1] 赵瑞梅,孙永平.强直性脊柱炎患者外周血TNF-α、IL-17、IL-23的表达及相关性分析[J].实用临床医药杂志,2015,19(9):38-40.

[2] 叶文芳,刘健,汪四海.强直性脊柱炎患者血清免疫球蛋白亚型、细胞因子的变化及相关性分析[J].免疫学杂志,2015,31(4): 362-365.

[3] 王作龙,钟乃风,马莉.检测不同活动期强直性脊柱炎患者外周血Th1、Th2和Treg细胞的意义[J].贵阳医学院学报,2015,40(4): 363-367

[4] 林洁华,黄闰月,江泽波,等.补肾强督治偻方对脂多糖刺激的小鼠RAW264.7细胞炎性细胞因子表达的影响[J].广州中医药大学学报,2015,32(2):285-289.

[5] Frauendorf E, von Goessel H, May E, et al. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin Exp Immunol. 2003;134(2): 351-359.

[6] 姜洋子.软骨干/祖细胞的特性及其促进关节软骨修复再生的研究[D].杭州:浙江大学,2012.

[7] 魏璐婉.hBMP-6基因修饰的骨髓间充质干细胞治疗类风湿性关节炎的实验研究[D].济南:山东大学,2012.

[8] 李治,毕平,刘伟,等.关于干细胞关节腔内注射修复软骨损伤的研究与进展[J].中外健康文摘,2014,11(6):276-277.

[9] 谭学新.强直性脊柱炎患者血免疫球蛋白、炎症指标及血液流变学指标的检测及临床意义[J].医学理论与实践,2015,28(11): 1426-1428.

[10] 岳枫,胡波.人类白细胞抗原、信号转导和转录激活因子、整合素与自身免疫病的相关性研究进展[J].中国医药导报,2015,12(14): 31-35.

[11] Neidhart M, Baraliakos X, Seemayer C, et al. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann Rheum Dis. 2009;68(8): 1334-1339.

[12] Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33(1):151-161.

[13] Chen MH, Chen WS, Lee HT, et al. Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. Clin Rheumatol. 2011;30(9):1181-1187.

[14] 李萍,王庆文.白细胞介素-23受体基因多态性与强直性脊柱炎遗传易感性关系的荟萃分析[J].中国药物与临床,2015,15(6): 756-761.

[15] Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 2012;64(6):1869-1878.

[16] Wong-Baeza I, Ridley A, Shaw J, et al. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol. 2013;190(7):3216-3224.

[17] 崔保刚.比较与分析不同影像学检测方法用于诊断强直性脊柱炎骶髂关节病变效果[J].中国CT和MRI杂志,2015,13(5):25-28.

[18] Slobodin G, Kessel A, Kofman N, et al. Phenotype of resting and activated monocyte-derived dendritic cells grown from peripheral blood of patients with ankylosing spondylitis. Inflammation. 2012;35(2):772-775.

[19] Zhao SS, Hu JW, Wang J, et al. Inverse correlation between CD4+ CD25high CD127low/- regulatory T-cells and serum immunoglobulin A in patients with new-onset ankylosing spondylitis. J Int Med Res. 2011;39(5):1968-1974.

[20] Ciccia F, Accardo-Palumbo A, Giardina A, et al. Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response.Arthritis Rheum. 2010; 62(12):3625-3634.

[21] Prevosto C, Goodall JC, Hill Gaston JS. Cytokine secretion by pathogen recognition receptor-stimulated dendritic cells in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2012;39(10):1918-1928.

[22] 程艳伟,李清山,杨坤,等.诱导性多潜能干细胞治疗骨关节炎的研究进展[J].中华医学杂志,2015,95(17):1354-1357.

[23] 崔云鹏,曹永平,刘恒.骨髓间充质干细胞治疗大鼠骨关节炎的实验研究[J].北京大学学报:医学版,2015,47(2):211-218.

[24] 王黎明,周建军,白雯,等.脐带间充质干细胞治疗17 例类风湿性关节炎患者的临床疗效观察[J].中国免疫学杂志,2010,26(7): 659-662.

[25] 刘鹄,任明亮,王潇娉,等.强直性脊柱炎患者骨髓间充质干细胞的生物学及免疫学特性[J].中国脊柱脊髓杂志,2012,22(6): 559-565.

[26] 舒强.类风湿关节炎,强直性脊柱炎和骨关节炎滑膜成纤维样细胞增殖与分化的体外研究[D].济南:山东大学,2006.

[27] 张荣华,欧阳菁.肾主骨生髓理论与骨髓间充质干细胞骨向分化[C].2007年全国中西医结合强直性脊柱炎专题研讨会论文集, 2007:83-87.

[28] 张华勇,冯学兵,王丹丹,等.异基因骨髓间充质干细胞移植治疗克罗恩病一例[J].中华医学杂志,2009,89(36):2590.

[29] 袁恒锋.Notch1-Hes信号通路在强直性脊柱炎髋关节韧带中的关联研究[D].上海:第二军医大学,2013.

[30] 徐薇,欧阳桂芳,冯鸣.自体外周血干细胞移植治疗急性髓细胞白血病合并强直性脊柱炎一例[J].中华内科杂志,2000,39(5):327.

[31] Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-1155.

[32] Wu Y, Ren M, Yang R, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13(1):R29.

[33] Lai NS, Yu HC, Chen HC, et al. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis Clin Exp Immunol. 2013;173(1):47-57.

[34] Bidad K, Salehi E, Jamshidi A, et al. Effect of all-transretinoic acid on Th17 and T regulatory cell subsets in patients with ankylosing spondylitis. J Rheumatol. 2013;40(4):476-483.

[35] 宋庆林.间充质干细胞治疗强直性脊柱炎36例临床分析[J].中国医学装备,2014,11(8):183-184.

[36] 刘鹄,任明亮,王潇娉,等.强直性脊柱炎患者骨髓间充质干细胞的生物学及免疫学特性[J].中国脊柱脊髓杂志,2012,22(6): 559-565.